(Q33761551)

29 July 2017

1 reference

title

The contingent valuation method in health care (English)

1 reference

29 July 2017

Klose T

1

1 reference

29 July 2017

publication date

1 May 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

47

1 reference

29 July 2017

issue

2

1 reference

29 July 2017

page(s)

97-123

1 reference

When do the "dollars" make sense? Toward a conceptual framework for contingent valuation studies in health care

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

The economic value of human life

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

The friction cost method for measuring indirect costs of disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Outcome measurement in economic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Appraising the use of contingent valuation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Economic evaluation in health care: is there a role for cost-benefit analysis?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Health care contingent valuation studies: a review and classification of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Valuation of the benefits of risk-free blood. Willingness to pay for hemoglobin solutions

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Consumers' preference and willingness to pay for pharmacist counselling for non-prescription medicines

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Acceptability of the once-a-month injectable contraceptives Cyclofem and Mesigyna in Egypt

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Patient interest in receiving audiotapes of information presented by their physicians. A survey of patients awaiting treatment in university and private practice settings

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Economic comparison of a tissue adhesive and suturing in the repair of pediatric facial lacerations.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

The comparability and reliability of five health-state valuation methods

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Economic considerations and outcome measurement in urge incontinence.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Mammography in older women: one-time and three-year adherence to guidelines.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Willingness to pay to shorten waiting time for cataract surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Selected economic issues in helminth control

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Bridging the gap between public expectations and public willingness to pay.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Economic evaluation of hypertension treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

A quality-of-life method for estimating the value of avoided morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

The value of diagnostic information to patients with suspected multiple sclerosis. Rochester-Toronto MRI Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Economic evaluation in primary health care: the case of Western Kenya community based health care project.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Are people willing and able to pay for health services?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Consumer demand for a pharmacist-conducted prescription counseling service

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Willingness to pay and willingness to accept: some evidence of an endowment effect

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Consumer Preferences for Verbal and Written Medication Information

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Relative importance to elderly patients of effectiveness, adverse effects, convenience and cost of antihypertensive medications. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Comparison of postoperative emesis, recovery profile, and analgesia in pediatric strabismus repair. Rectal acetaminophen versus intravenous fentanyl-droperidol.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Feasibility of willingness-to-pay measurement in chronic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Willingness to pay and accept risks to cure chronic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Willingness to pay for reduction in fatality risk: an exploratory survey

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Are adolescents able and willing to pay the fee for confidential health care?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

What Do Patients Value?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Willingness to pay for publicly-provided goods. A possible measure of benefit?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Risk reduction from low osmolality contrast media. What do patients think it is worth?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Willingness to pay for antihypertensive therapy--results of a Swedish pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Willingness to pay for antihypertensive therapy--further results.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Cost-benefit analysis of non-pharmacological treatment of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Economic evaluation of lipid lowering — A feasibility test of the contingent valuation approach

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Willingness to pay for lipid lowering: a health production function approach

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Contingent valuation of supplemental health care in Israel

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

The willingness to pay for in vitro fertilization: a pilot study using contingent valuation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Couples' willingness to pay for IVF/ET

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Using willingness to pay to assess the benefits of assisted reproductive techniques

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Are people willing to pay for a community-based preventive program

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Willingness to pay: a valid and reliable measure of health state preference?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Counting the benefits of screening: a pilot study of willingness to pay for cystic fibrosis carrier screening

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Stepwise or couple antenatal carrier screening for cystic fibrosis?: women's preferences and willingness to pay

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Willingness to pay for antenatal carrier screening for cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Using willingness to pay to value close substitutes: carrier screening for cystic fibrosis revisited.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Using willingness to pay to value alternative models of antenatal care

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

A comparative study of seven measures of patient satisfaction

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Value for money? A contingent valuation study of the optimal size of the Swedish health care budget

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Assessing the economic value of a new antidepressant. A willingness-to-pay approach

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Estimating the economic benefits of avoiding food-borne risk: is 'willingness to pay' feasible?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Preferences for home vs hospital care among low-risk patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Measuring heart patients' willingness to pay for changes in angina symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Willingness to pay for reductions in angina pectoris attacks

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

An empirical note on willingness to pay and starting-point bias.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Willingness to pay for child survival: results of a national survey in Central African Republic

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Valuation of health changes with the contingent valuation method: A test of scope and question order effects

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

To be, or not to be, that is the question: An empirical study of the WTP for an increased life expectancy at an advanced age

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

On the Value of Changes in Life Expectancy: Blips Versus Parametric Changes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Willingness to pay for district hospital services in rural Tanzania

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Patients' willingness to pay for autologous blood donation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Willingness to pay for poison control centers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Does "process utility" exist? A case study of willingness to pay for laparoscopic cholecystectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Willingness to pay for antihypertensive care: evidence from a staff-model HMO.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Determinants of willingness to pay taxes for a community-based prevention programme

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Willingness to pay for reduced incontinence symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Willingness to pay for health insurance in a developing economy. A pilot study of the informal sector of Ghana using contingent valuation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Measurement of consumer-patient preferences using a hybrid contingent valuation method

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: an assessment of amifostine cytoprotection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

MR and conventional angiography: work in progress toward assessing utility in radiology.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

The impact of hormone replacement therapy on quality of life and willingness to pay

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

Economic evaluation in healthcare. A brief history and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

The trade-off between severity of illness and treatment effect in cost-value analysis of health care

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900010-X

7 January 2021

10.1016/S0168-8510(99)00010-X

Identifiers

DOI

1 reference

29 July 2017

1 reference